Falsified Ozempic pens identified at two wholesalers in the UK

19 October 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late yesterday confirmed that pre-filled pens falsely labeled as the diabetes medicine Ozempic (semaglutide, 1mg, solution for injection) have been identified at two UK wholesalers.

The genuine Ozempic is marketed by Danish diabetes care giant Novo Nordisk (NOV: N) for the treatment of type 2 diabetes. Semaglutide has been in short supply, largely because it is also the active ingredient of Novo Nordisk's hugely successful obesity treatment Wegovy, with people wanting to achieve weight loss snapping up Ozempic prescriptions.

All affected pens have been recalled and accounted for, and none of the pens have been supplied to UK patients, the Agency noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK